Klotho Neurosciences Reports Material Agreement & Equity Sales

Ticker: GRMLW · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1907223

Sentiment: neutral

Topics: material-agreement, equity-sale, name-change

Related Tickers: KLTO

TL;DR

Klotho Neurosciences inked a deal and sold stock on June 9th.

AI Summary

Klotho Neurosciences, Inc. filed an 8-K on June 13, 2025, reporting on events that occurred on June 9, 2025. The filing indicates an entry into a material definitive agreement and unregistered sales of equity securities. The company was formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp.

Why It Matters

This filing signals significant corporate activity, including new agreements and the issuance of equity, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves unregistered sales of equity securities, which can sometimes indicate less transparency or potential dilution for existing shareholders.

Key Players & Entities

FAQ

What was the nature of the material definitive agreement entered into by Klotho Neurosciences?

The filing does not specify the details of the material definitive agreement, only that one was entered into on June 9, 2025.

What type of equity securities were sold in the unregistered sale?

The filing mentions 'Unregistered Sales of Equity Securities' but does not specify the type of securities sold.

When did Klotho Neurosciences change its name from ANEW Medical, Inc.?

The date of the name change from ANEW Medical, Inc. was June 24, 2024.

What is Klotho Neurosciences' Standard Industrial Classification (SIC) code?

Klotho Neurosciences' SIC code is 2836, for Biological Products (No Diagnostic Substances).

What is the company's fiscal year end?

The company's fiscal year end is December 31.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Klotho Neurosciences, Inc. (GRMLW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing